Parameter
| Biomarker | EGFR Amp/EGFRvIII Mut | Full name | EGFR Amplification/EGFRvIII Mutation | Molecular Type | Gene Mutation/Amplification |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Prediction, Prognosis |
| Disease | Glioblastoma | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue/Plasma (FISH, NGS, IHC) | ||
| Pathobiological Mechanisms | EGFR amplification activates the PI3K/AKT pathway; EGFRvIII mutation leads to sustained receptor activation, both promoting tumor proliferation, invasion, and treatment resistance. | ||||
| Clinical Availability Status | Under clinical validation | ||||
| Notes and Dynamics | EGFR inhibitors (cetuximab) combined with TMZ show synergistic efficacy in EGFR-amplified patients; EGFRvIII-positive patients are more sensitive to immunotherapy. | ||||